Novo Nordisk ADR (NYSE:NVO) currently has a daily average trading volume of 5.16M but it saw 3647131 shares traded in last market. With a market cap of 362.59B USD, the company’s current market price of $108.61 came falling about -2.76 while comparing to the previous closing price of $111.69. In past 52 weeks, the stock remained buoying in the range of price level as high as $148.15 and as low as $94.96. In the recent trading on the day, stock has struck highest price mark of $108.5616 while lowest mark touched by it was $111.1691.
Taking a look at 20-day trading activity of Novo Nordisk ADR (NVO) gives us an average price of $106.65, while its current price level is -26.69% below from 52-week high level whereas it is 14.37% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $110.92 while that of 200 days or SMA-200 reads an average of $126.95. A closer look into the stock’s movement over the week reveals that its volatility is standing at 2.08% during that period while stretching the period over a month that decreases to 1.79%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 48.94 which implies that the stock is in neutral territory.
The company’s shares got several price updates from the analyst firms in past one month and most recent of them is from the Goldman which initiated the stock as “Buy” in its note to investors issued on May 30, 2024, recommending a price target of $156 for it. Morgan Stanley also issued its recommendations for the stock as it initiated the price target for the stock is $120.
Over the week, NVO’s stock price is moving -0.19% down while it is 1.45% when we observe its performance for the past one month. Year-to-date it is 4.99% up and over the past year, the stock is showing an upside performance of 12.89%.
The company is expected to be releasing its next quarterly report in January, for which analysts forecasted an EPS of 6.39 while estimate for next year EPS is 22.74. In next quarter, company is expected to be making quarterly sales of $79.93B as analysts are expecting the sales for current fiscal year at $286.67B and seeing the company making $344.94B in sales next year. Moreover, analysts are in estimates of $81.26B for current-quarter revenue.
Currently, Novo Nordisk ADR’s total number of outstanding shares is 3.34B. Company’s return on investment (ROI) stands at 53.52% and return on equity (ROE) at 88.20%. It has a price to earnings ratio (P/E ratio) of 35.22 while having a 26.81 of forward P/E ratio. Stock’s beta reads 0.40. Stock has a price to book (P/B) ratio of 20.10 while price to sale or P/S ratio amounts to 9.22. Its return on asset (ROA) is 26.99% on average.
